InvestorsHub Logo
Followers 115
Posts 20074
Boards Moderated 0
Alias Born 06/13/2011

Re: Fenix1357 post# 80

Friday, 03/01/2019 6:43:13 PM

Friday, March 01, 2019 6:43:13 PM

Post# of 332
Hi Fen
Quick note as previous post got lost .
Agree with your number ( from a quick look )

So all 70,000 fistula procedures need the application of Von to generate your $166m in savings
How much can you charge per application then .

Re time to final abandonment. If this is improved by only 17% ( half previous trial ) but the ability to use the fistula in first year is increased by 30% ...how much can you charge for the drug.

Lots of moving parts assuming both end pts are stat sig....to determine what they can charge .

I'm apparently more concerned about the time to abandonment end pt then most .
The P value in the prior trial P.048 from memory tells me theres almost a 20% chance that the degree of benefit could be very different in the final trial....just my very basic understanding of bio stats.

My wife seems most concerned about time to abandonment , less on loss of primary patency ( blood flow ) as they apparently often do procedures to ensure proper blood flow .
Its when the fistula has to be abandoned ...thats the hard end pt

JMO
Kiwi